Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, & Forecasts, 2025
327 Pages, 48-Hour Sale for 40% Off
For 48 hours only, you can claim it for a rare 40% off.
Why This Report Matters
Umbilical cord blood has been a clinically accepted HSC source for 37+ years, yet utilization still trails bone marrow and peripheral blood due to cell dose and engraftment constraints.
At the same time, cord blood and tissue and placenta-derived cells are central to active research and development activity in NK, CAR-NK/T, and iPSC workflows.
This report quantifies where the field stands today and analyzes how revenues, market trends, and strategic opportunities are expected to evolve through 2032.
Anchor Metrics Covered in the Report
Global donor and unit landscape: Reports rates of donors and cord blood units (CBUs) registered across 57 countries, including CBUs shipped for transplantation; identifies world’s largest cord blood banks by inventory (total units stored).
Transplant trends: Compares use of peripheral blood (PB), blood marrow (BM), and cord blood (CB); regional transplant activity; and cost benchmarks through one-year post-HSCT.
Clinical pipeline: Current counts and phase distribution for cord blood, cord tissue, placental tissue, and expanded CBU trials.
Market outlook: Global market size figures for both cord blood and cord tissue (current, with forecasts through 2032); public vs. private share, geographic distribution, additional segmentation by transplantation vs. regenerative medicine (RM), and indication-level analysis.
What’s Inside the Report (Selected Highlights)
Banks & business models: Public, private, hybrid, and community bank structures; cost and revenue analyses; release-rate dynamics; U.S. and EU cord blood unit (CBU) pricing; and inventory rankings.
Accreditations & regulatory context: AABB, FACT, FDA registration/BLA/IND, HTA, and TGA—processes, standards, and coverage by bank.
Patent landscape (2000 to present): Cord blood, cord tissue, placental tissue, and expansion technologies; applications by year/jurisdiction, legal status, and leading assignees and inventors.
Publications & trials: Detailed analysis of scientific publications and clinical trial rate data for cord blood, cord tissue, and placenta; expansion-method literature; leading sponsors and funders; and companies leading the ongoing studies and trials.
Processing & expansion tech: Comparative performance across MaxCell/plasma depletion, HES, PrepaCyte-CB, SEPAX, AXP, TotiCyte, MacoPress Smart; anticoagulants, cryopreservation, and leading and emerging ex vivo expansion strategies.
Supply & matching: Global cord blood unit (CBU) availability by region, race/ethnicity breakdowns in U.S. registries, HLA typing and international exchange statistics, and beyond.
Indications & outcomes: Malignant and non-malignant HSCT indications; regenerative medicine targets (e.g., autism, CP, Alzheimer’s, diabetes, MS, stroke, cardiac).
Company profiles: Deep dives on 90+ organizations (cord blood banks, suppliers, CRO/CMOs, and therapeutics developers), including pricing examples, accreditations, pipelines, and strategic advantages.
Who Should Read the Report
• Cell & gene therapy developers assessing allogeneic supply, expansion strategies, and future release rates.
• Cord blood/tissue banks stress-testing unit economics, pricing, and accreditation pathways.
• Investors and BD teams benchmarking market share, growth drivers, and IP concentrations.
• Clinicians and transplant centers comparing processing technologies, engraftment timelines, and cost-of-care data.
Deliverables
This report delivers an analytical, data-driven narrative accompanied by figures and tables detailing inventories, pricing, clinical activity, processing technologies, leading competitors, and market forecasts, organized for direct use in diligence, strategy, and board materials.
To review the report's Table of Contents and Executive Summary, use the link below.
Best regards,
Lance Breastgoff
Head of Market Research
BioInformant
p.s. Remember to act fast, because this offer for 40% off expires Friday, November 7th, at midnight.
|
